A two-stage dose selection strategy in phase I trials with wide dose ranges

Journal of Biopharmaceutical Statistics

Volumn 10, Issue 3, 2000, Pages 319-333

  Wang, O ^a   Faries, D E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Continual reassessment methods; Logistic dose ranging strategy; Maximum tolerated dose; Phase I designs; Two stage designs

Indexed keywords

ARTICLE; BIOSTATISTICS; CLINICAL RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESEARCH; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM LIKELIHOOD METHOD; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS;

BAYES THEOREM; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; LOGISTIC MODELS; MAXIMUM TOLERATED DOSE;

EID: 0033883272     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-100102497     Document Type: Article

References (8)

1. Current phase I/II designs: Are they adequate?
2. Practical modifications of the continual reassessment method for phase I cancer clinical trials
3. Design and analysis of Phase I clinical trials
4. Continual reassessment method: A practical design for phase I clinical trials in cancer
5. Some practical improvements in the continual reassessment method for phase I studies
6. A logistic dose-ranging method for phase I clinical investigations trial
7. Potential roles for preclinical pharmacology in phase I clinical trials
8. Continual reassessment method: A likelihood approach